TUCSON, Ariz.–HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced that Lee Hartwell, Ph.D., President & Director, Fred Hutchinson Cancer Research Center, 2001 Nobel Laureate, and Timothy Yeatman, M.D., Executive Vice President, Co-Founder & C.S.O. of M2Gen, have agreed to join HTG’s Scientific Advisory Board (SAB).

“HTG’s technology is perfectly suited to accelerate the process of identifying and validating biomarkers that will improve outcomes and lower costs”

“HTG’s technology is perfectly suited to accelerate the process of identifying and validating biomarkers that will improve outcomes and lower costs,” said Dr. Hartwell. “The qNPA technology shows great promise in working with Formalin Fixed Paraffin Embedded (FFPE) samples which initially got my attention.” Dr. Yeatman added, “Being able to work with older tissue samples will open up a lot of new information that is valuable for researchers.”

“We are so excited to have two individuals of Lee and Tim’s experience and capabilities join our SAB as we continue to transition HTG into a personalized medicine and diagnostic company. We were looking for advisors who had substantial knowledge and experience in translational medicine and diagnostics and we have certainly found just that with Dr. Hartwell and Dr. Yeatman,” said TJ Johnson CEO of HTG.

About HTG

Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com